PAH diagnosis timing study
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at the timing between first symptoms and diagnosis of pulmonary arterial hypertension (PAH). It aims to better understand how quickly patients get diagnosed after symptoms appear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PAH (not other types of pulmonary hypertension).
- Your doctor knows when your first symptoms started (or can estimate it).
- The date of your official PAH diagnosis is known.
- Your PAH diagnosis was confirmed by a right heart catheterization (not just by an echocardiogram or exam).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to validate a questionnaire that measures how well patients understand pulmonary hypertension. If you have been diagnosed with Group 1 Pulmonary Arterial Hypertension (PAH) and can read the questionnaire, you may be able to help researchers make sure it's a useful tool.
This is a long-term study that enrolls people who have been diagnosed with pulmonary hypertension (high blood pressure in the lung arteries). It collects medical information over time to better understand the condition and what to expect.
This study uses heart imaging tests to better understand pulmonary arterial hypertension (PAH) and predict outcomes. It may help doctors tailor treatment for people with PAH.
This trial uses special ultrasound imaging to look at how well the heart works in people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to understand heart changes before and after starting PAH treatment.
This study looks at how things in your environment (like pollution, diet, or lifestyle) might be linked to pulmonary hypertension. By comparing two groups of patients, researchers hope to find new clues about the condition.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
Hear when a new Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.